BRISBANE, Australia--(BUSINESS WIRE)--Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy’s Limited for marketing fondaparinux sodium for injection (the generic version of GlaxoSmithKline’s Arixtra®) in all territories outside of North America. This agreement does not in any way alter the existing arrangements between the companies for the manufacture and North American marketing of fondaparinux.
